{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 21 of 81', '24 weeks and other thresholds (e.g. >3, >7, >10, >15, >20), and the proportions with', 'these improvements in the other KCCQ domains OSS, CSS, TSS and SFS.', 'To evaluate the efficacy of vericiguat 10 mg in comparison to placebo in decreasing', 'the proportion of patients with KCCQ PLS decline from baseline by >5 points at', '24 weeks and the proportions with decline in the other KCCQ domains OSS, CSS,', 'TSS and SFS.', 'To evaluate the efficacy of vericiguat 15 mg in comparison to placebo in decreasing', 'the proportion of patients with KCCQ PLS decline from baseline by >5 points at', '24 weeks and the proportions with decline in the other KCCQ domains OSS, CSS,', 'TSS and SFS.', 'Other objectives:', 'To evaluate the efficacy of vericiguat 10 mg and the efficacy of vericiguat 15 mg in', 'comparison to placebo on improving:', 'Symptom frequency as measured by the KCCQ SFS', 'Perceived exertion experienced by patients during 6MWT as measured by', 'Borg CR 10.', 'Other patient-reported outcomes such as the generic health-related quality of', 'life measure EQ-5D-5L and the Fried-based frailty score', 'NYHA class', 'Laboratory variables such as NT-proBNP from baseline to 24 weeks', 'To collect and summarize death including cardiovascular death and CV', 'hospitalizations including heart failure hospitalizations, MI and stroke, and outpatient', 'HF events.', 'To analyze the cumulative distribution function of KCCQ PLS, OSS, CSS, TSS and', 'SFS change from baseline at 24 weeks.', 'To evaluate PK of vericiguat in patients with HFpEF, and', 'To evaluate the concentration-QTc relationship of vericiguat at the 15 mg dose level.', 'Optional pharmacogenetic research: To explore the relationship between genetic', 'variation and clinical characteristics of patients, independent and dependent of the', 'treatment administered. Variations across the human genome may be analyzed for', 'association with clinical data collected in this study.', 'To evaluate further biomarkers to investigate the drug (i.e. mode-of-action-related', 'effect and / or safety) and / or the mechanisms of the disease', 'Optional accelerometry substudy: to collect exploratory data by activity tracking']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 22 of 81', '5.', 'Study design', 'Design overview', 'This is a randomized parallel-group, placebo-controlled, double-blind, multi-center trial of', 'vericiguat in patients with HFpEF to be conducted in conformance with GCP. Approximately', '735 patients will be randomized as described in Figure 5-1 to evaluate the efficacy of', 'vericiguat 10 mg and 15 mg in comparison to placebo on improving physical functioning', 'from baseline to week 24. To reduce heterogeneity in the studied population patients younger', 'than 45 years of age are not eligible. Patients are expected to be on a background treatment', 'for co-morbidities like hypertension (see Section 8.1), and diuretics in the presence of', 'symptoms due to volume overload.', 'Screening may be initiated any time after admission of a patient to the hospital for HF, before', 'or after discharge, and up to 6 months after hospitalization for HF. Use of IV diuretic', 'treatment for HF, even without hospitalization, is indicative of HF decompensation and', 'accepted as a qualifying HF event equivalent to hospitalization. The most recent', 'decompensation should be considered for qualifying the patient for the study. In either', 'scenario, HF must be the primary reason for hospitalization or IV diuretic treatment. Patients', 'will be randomized within up to 4 weeks after the screening visit (see Section 7.3) and within', 'up to 6 months after the onset of the qualifying event of hospitalization for HF or treatment', 'with IV diuretic for HF (see Figure 5-1), and treated as given in Sections 7.1 and 7.3.', 'Primary endpoint assessment is at week 24. All patients will be followed until study', 'completion to assess for vital status and all study endpoints.', 'Figure 5-1 Study design', '15 mg vericiguat', '10 mg', 'Randomization', '5 mg', '10 mg vericiguat', '1:1:1', 'Previous HF event', '2.5 mg', 'within 6 months', 'N 735', '5 mg', 'elevated NT-proBNP', '2.5 mg', 'NYHA 2/3', 'R', 'EF >45%', 'Placebo', 'LVH and/or LAE', 'Screening', '4 weeks', 'Week 2 Week 4 Week 6 Week 8', 'Week 12', 'Week 18', 'End of Follow-up', 'treatment Visit', 'Week 24 Week 28', 'V1', 'V2', 'V3', 'V4', 'V5', 'V6', 'V7', 'V8', 'V9', 'V10', 'Treatment duration: 24 weeks', 'FU', 'Primary end point', 'KCCQ-PLS', 'at Week 24', 'EF, ejection fraction; FU, follow-up; HF, heart failure; KCCQ, Kansas City Cardiomyopathy', 'Questionnaire; LAE, left atrial enlargement; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal', 'pro-brain natriuretic peptide; NYHA, New York Heart Association; PLS, physical limitation score;', 'V, Visit.', 'KCCQ as the entire questionnaire is administered, not just the PLS domain.']\n\n###\n\n", "completion": "END"}